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Background: Klotho is a single-pass transmembrane protein, which appears to be implicated in aging. The purpose
of the present study was to characterize the relationship between the soluble Klotho level and renal function in
patients with various degrees of chronic kidney disease (CKD).
Methods: The levels of soluble Klotho in the serum and urine obtained from one hundred thirty-one CKD patients
were determined by a sandwich enzyme-linked immunosorbent assay system.
Results: The amount of urinary excreted Klotho during the 24 hr period ranged from 1.6 to 5178 ng/day (median
427 ng/day; interquartile range [IR] 56.8-1293.1), and the serum Klotho concentration ranged from 163.9 to
2123.7 pg/ml (median 759.7 pg/ml; IR 579.5-1069.1). The estimated glomerular filtration rate (eGFR) was significantly
correlated with the log-transformed values of the amount of 24 hr urinary excreted Klotho (r = 0.407, p < 0.01) and
the serum Klotho levels (r = 0.232, p < 0.01). However, a stepwise multiple regression analysis identified eGFR to be
a variable independently associated only with the log-transformed value of the amount of 24-hr urinary excreted
Klotho but not with the log-transformed serum Klotho concentration. Despite the strong correlation between
random urine protein-to-creatinine ratio and the 24 hr urinary protein excretion (r = 0.834, p < 0.01), a moderate
linear association was observed between the log-transformed value of the amount of 24 hr urinary excreted Klotho
and that of the urinary Klotho-to-creatinine ratio (Klotho/Cr) in random urine specimens (r = 0.726, p < 0.01).
Conclusions: The amount of urinary Klotho, rather than the serum Klotho levels, should be linked to the
magnitude of the functioning nephrons in CKD patients. The use of random urine Klotho/Cr as a surrogate for the
amount of 24-hr urinary excreted Klotho needs to be evaluated more carefully.
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Klotho is a single-pass transmembrane protein with a
long extracellular domain and a short cytoplasmic tail,
which appears to be implicated in aging, and regulates
both the mineral transport and signaling mediated by
fibroblast growth factor 23 (FGF23) [1,2]. The kidneys,
parathyroid gland, and choroid plexus of the brain have
been identified on as the sites where the Klotho is* Correspondence: tetsu-a@jichi.ac.jp
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reproduction in any medium, provided the orpredominantly expressed, while the extracellular domain
of Klotho may be cleaved and released into the blood,
cerebrospinal fluid, and urine, as a soluble form [2-5].
Recently, we have shown that the total amount of urin-
ary excreted soluble Klotho is correlated with the re-
sidual renal function among patients with advanced
chronic kidney disease (CKD) [6]. However, the qualita-
tive and quantitative analyses regarding the soluble
Klotho in the subjects with different stages of CKD have
been insufficient. To remedy this, we performed a cross-
sectional study to characterize the level soluble Klotho
in patients with various degrees of chronic renall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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teristics on the soluble Klotho level was also
investigated.
Methods
Between June 2011 and February 2012, 131 ambulatory
CKD patients with different stages of disease were
recruited and enrolled in the present study. The stages
of CKD were determined by the estimated glomerular
filtration rate (eGFR) based on the abbreviated Modifica-
tion of Diet in Renal Disease (MDRD) Study equation
with a Japanese coefficient, calculated by the eGFR (ml/
min/1.73 m2) = 0.881 × 186 × Age –0.203 × serum creatin-
ine -1.154 (if female × 0.742) [7,8]. Patients receiving renal
replacement therapy were excluded from the study. All
subjects were being followed at the renal unit of Jichi
Medical School Hospital and were stable. None were
critically ill at the time of the study. The patients’ usual
medications, such as anti-hypertensive agents, erythro-
poietin, diuretics, oral active vitamin D sterols including
calcitriol and alfacalcidol, and CaCO3 as a phosphate
binder, were continued during the study period. The re-
search protocol was approved by the Medical Ethics
Committee of Jichi Medical University, and all subjects
included in the present study provided their informed
consent.
After a sample of each urine specimen voided during a
24 hr period was collected, random urine samples were
obtained when a blood sample for the study was also
collected. Both the urine and blood sample were col-
lected in the morning. The total protein, albumin, so-
dium, chloride, potassium, calcium, inorganic phosphate,
urea, and creatinine levels in the serum were all mea-
sured just after the collection. The volume, total protein,
albumin, sodium, chloride, potassium, calcium, inorganic
phosphate, urea, and creatinine were measured in the
24-hour urine collection, and the same parameters were
also evaluated in the random urine collections. The soluble
Klotho concentrations were determined in each sample by a
solid-phase sandwich enzyme-linked immunosorbent assay
(ELISA) kit (Immuno-Biological Laboratories, Gunma,
Japan) according to the manufacturer’s protocol [6,9]. The
minimum level of detectability of the assay was 6.15 pg/ml,
and the minimum level was below the serum and urine
concentrations that were found in the present study. The
intra- and inter-assay coefficients of variation were <10%
[9]. The serum FGF23 levels were determined using a
sandwich ELISA kit (Kainos Laboratories, Tokyo, Japan).
The inter-assay variation in the normal and elevated con-
centration range was less than 6% [10]. An electrochemi-
luminence immunoassay for determining the serum
intact parathyroid hormone (iPTH) levels and a double
antibody radioimmunoassay for identifying the serum
calcitriol levels were performed by a commercially basedclinical diagnostic testing service (SRL, Inc., Tokyo,
Japan). The serum soluble Klotho concentration or the
amount of urinary soluble Klotho was normalized by a
common logarithm (Log) when a reduction of skewness
was required.
The data are expressed as either the number of partici-
pants or as the percentage (%) of the study population.
The remaining data are expressed as the means ± SD, or
medians and interquartile range (IR) for variables of a
skewed distribution. The groups were compared using a
one-way analysis of variance with Dunnet’s method for
normal distributions and the Kruskal–Wallis test with
Dunn’s method for skewed distributions. Categorical
variables were assessed using the chi-square test with
nonparametric post-hoc pairwise comparisons [11,12].
The relationships between the CKD stages and the
amount of 24 hr urinary excreted Klotho or the serum
levels of Klotho were assessed by Spearman’s correla-
tions (Spearman’s rho), while the various linear relation-
ships were assessed by Pearson’s product moment
correlation if deemed necessary. A stepwise forward
multiple regression analysis was conducted considering
soluble Klotho as a dependent variable, and the eGFR,
age, amount of 24 hr urinary excreted protein, serum
total protein, serum albumin, serum phosphorus, serum
iPTH, and serum calcitriol levels were included in the
statistical model. This method was also applied to evalu-
ate the significance of the soluble urinary Klotho level,
including the 24 hr urinary excreted Klotho and random
urinary Klotho-to-creatinine ratio, on eGFR as an inde-
pendent predictive variable. The F-values for the inclu-
sion and exclusion of variables was set at 4.0. The
differences between the independent correlation coeffi-
cients were compared statistically by performing a
Fisher’s r-to-z transformation [13-15]. P-values <0.05
were considered to be statistically significant. The statis-
tical analyses were performed using the SigmaPlot soft-
ware program 11 for Windows (Systat Software, Inc.,
San Jose, CA) unless otherwise stated.
Results
The clinical profiles of the 131 patients with various
degrees of CKD in the present study are summarized in
Table 1. The sex distributions, levels of serum albumin,
prevalence of nephrotic syndrome (NS), and the clinical
use of CaCO3 as a phosphate binder were comparable
among the five CKD groups, while the differences for
the rest of the parameters among the five groups of
CKD were greater than would normally be expected
by chance alone. The main causes of CKD were chronic
glomerulonephritis in 80 patients (61%) (including biopsy-
proven IgA nephropathy [n = 40]), diabetic nephropathy
in 21 patients (16%), hypertensive nephrosclerosis in 13
patients (10%), lupus nephritis in five patients (4%),
Table 1 Clinical profiles of CKD patients
CKD stages
All 1 2 3 4 5 p value
Clinical and laboratory characteristics
Patients, n (M/F) 131 (71/60) 18 (6/12) 27 (17/10) 29 (15/14) 18 (11/7) 39 (22/17) p =
0.348
Age (years) 56 ± 18 36 ± 16 53 ± 18** 55 ± 16** 68 ± 16** 64 ± 15** p <
0.001
Serum creatinine (mg/dl) 2.7 ± 2.8 0.5 ± 0.1 0.8 ± 0.2 1.2 ± 0.3 2.5 ± 0.6** 6.5 ± 2.7** p <
0.001
eGFR (ml/min/1.73 m2) 46.3 ± 37.5 112.8 ± 19.5 74.7 ± 9.4** 46.7 ± 8.6** 19.9 ± 3.8** 7.9 ± 3.0** p <
0.001
Urinary excreated protein (g/day) 2.8 ± 2.1 2.6 ± 1.3 2.2 ± 1.5 2.8 ± 1.7 4.3 ± 3.8* 2.5 ± 2.2 p =
0.039
Urinary excreted albumin (g/day) 1.9 ± 1.0 1.2 ± 0.9 1.5 ± 0.9 1.7 ± 1.1 3.1 ± 2.2* 1.5 ± 1.1 p =
0.017
Serum total protein (g/dl) 6.1 ± 0.9 6.1 ± 1.2 6.2 ± 0.2 6.5 ± 0.9 5.5 ± 1.2 6.2 ± 0.7 p =
0.023
Serum albumin (g/dl) 3.1 ± 0.8 3.1 ± 0.9 2.9 ± 0.8 3.2 ± 0.7 2.6 ± 0.9 3.1 ± 0.7 p =
0.101
Serum calcium (mg/dl) 8.6 ± 0.9 8.9 ± 0.7 8.7 ± 0.9 8.9 ± 0.5 8.2 ± 0.9* 8.2 ± 0.9* p <
0.001
Serum phosphorus (mg/dl) 3.9 ± 1.3 3.1 ± 0.7 3.1 ± 0.5 3.12 ± 0.5 4.1 ± 1.3 5.2 ± 1.4* p <
0.001




























Serum calcitriol (pg/ml) 40.1 ± 26.0 57.1 ± 26.2 59.8 ± 23.9 52.2 ± 23.9 23.1 ± 9.5** 17.6 ± 9.4** p <
0.001
Prevalence of NS No.(%) 34 (26) 3 (17) 5 (19) 6 (21) 8 (44) 12 (31) p =
0.225
Medications, n (%)
Anti-hypertensive agent(s) 67 (51) 4 (36) 11 (41) 5 (17) 10 (56) 37 (95)** p <
0.001
Diuretic(s) 35 (27) 1 (6) 4 (15) 7 (24) 5 (28) 18 (49)** p =
0.008
CaCO3 as an phosphate binder 3 (2) 0 (0) 0 (0) 0 (0) 0 (0) 3 (8) p =
0.124
Active Vitamin D sterol (calcitriol or
alfacalcidol)
9 (7) 0 (0) 0 (0) 0 (0) 1 (6) 8 (21)* p =
0.002
Erythropoietin 30 (23) 0 (0) 0 (0) 0 (0) 2 (11) 28 (72)** p <
0.001
*p < 0.05 vs CKD stage I, **p < 0.01 vs CKD stage I.
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in the remaining nine patients was uncertain or under in-
vestigation. There were 25 patients (19%) with diabetes.
Soluble Klotho was detectable in both the urine and
serum of our CKD subjects. The amount of urinary
excreted Klotho during the 24 hr period ranged from 1.6
to 5178 ng/day (median 427 ng/day; IR 56.8-1293.1),
and the serum Klotho concentration ranged from 163.9
to 2123.7 pg/ml (median 759.7 pg/ml; IR 579.5-1069.1).
No significant differences in these values between the
male and female subjects were observed. The amountof 24 hr urinary excreted soluble Klotho trended to-
wards lower values with advancing stages of CKD
(overall p < 0.001). Only the amounts of urinary excreted
soluble Klotho at CKD stages 4 and 5 were significantly
lower compared with CKD stage 1 (Figure 1a), while an
inverse correlation between the amount of urinary
excreted soluble Klotho and stages of CKD was con-
firmed (Spearman’s rho value = −0.462, p < 0.01). The
serum soluble Klotho levels were statistically different
among five CKD groups (overall p = 0.009) (Figure 1b);
also, an inverse correlation was observed between the
Figure 1 Box plots of the amount of 24 hr urinary excreted Klotho (a) and the serum Klotho levels (b) by CKD stages. The lower border
of the box and the upper border of the box represent the first quartile and third quartile, respectively. The whiskers indicate 1.5 times the IR
above and below the 25th and 75th percentiles. Outliers (values >1.5 times the IR) are represented by closed circles. *p < 0.05 vs CKD stage I.
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(Spearman’s rho value = −0.252, p < 0.01). The log-
transformed value of the amount of 24 hr urinary
excreted Klotho significantly correlated with the eGFR
and serum calcitriol (Figure 2a, b). It correlated with the
amount of urinary excreted total protein (r = 0.249, p <
0.01) and albumin (r = 0.250, p < 0.01) found in the 24 hr
urine collection, serum total protein (r = −0.235, p <
0.01), serum albumin (r = −0.182, p = 0.0374), serumFigure 2 Not only the urinary excreted Klotho but also the serum Klo
transformed value of the amount of 24 hr urinary excreted Klotho significa
significant associations between the log transformed serum Klotho levels a
Klotho levels and serum calcitriol as well (d).phosphorus (r = −0.329, p < 0.01), serum iPTH (r =
−0.234, p < 0.01), and age (r = −0.304, p < 0.01), as well,
but not with serum calcium and that of FGF23. The log-
transformed serum Klotho concentration did not correl-
ate with the 24 hr urinary excreted protein, and total pro-
tein, albumin, calcium, phosphorus, FGF23, and iPTH
found in the serum but it did correlate with the eGFR
(Figure 2c), serum calcitriol (Figure 2d), and age (r =
−0.172, p < 0.05). The serum calcitriol levels correlatedtho associated with both eGFR and serum calcitriol. The log
ntly correlated with the eGFR (a) and serum calcitriol (b). There were
nd the eGFR (c) and between the log-transformed serum soluble
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associated with iPTH (r = −0.426, p < 0.01) and FGF23 (r
= −0.433, p < 0.01). A significant association between the
log-transformed value of the amount of 24 hr urinary
excreted Klotho and that of the serum soluble Klotho
levels (r = −0.403, p < 0.01) was also observed.
A stepwise multiple regression analysis identified the
eGFR (ß = 0.482) and 24-hr urinary protein (ß = 0.351)
as predictive variables for the log-transformed value of
the amount of 24 hr urinary excreted Klotho (Total
R2 = 0.284, p < 0.001), while only the serum calcitriol
(ß = 0.267) was selected as an explanatory factor for the
serum Klotho concentration (Total R2 = 0.0713, p < 0.01).
The log-transformed value of the amount of 24 hr
urinary excreted Klotho in the 97 CKD subjects without
NS correlated with the eGFR (r = 0.506, p < 0.01), serum
iPTH (r = −0.225, p = 0.0264), serum calcitriol (r = 0.424,
p < 0.01), and age (r = −0.348, p < 0.01); while the log-
transformed serum Klotho concentration correlated
with the eGFR (r = 0.263, p < 0.01) and serum calcitriol
(r = 0.337, p < 0.01). Only the eGFR was included as a
predictive variable for the log-transformed value of the
amount of 24 hr urinary excreted Klotho (ß = 0.506,
Total R2 = 0.256, p < 0.01), and serum calcitriol was
included as a predictive variable for the log-transformed
serum Klotho concentration (ß = 0.337, Total R2 = 0.113,
p < 0.01).
Regardless of the presence or absence of NS, the log-
transformed value of the amount of 24 hr urinary
excreted Klotho was significantly correlated with that of
the random urine Klotho-to-creatinine ratio (Klotho/Cr),
and no significant difference was observed between the r
values among the overall patient population and the
patients without NS (z = 0.53, p = 0.5947) (Figures 3a, b).
The correlation coefficient for the linear relationship be-
tween the amount of urinary excreted protein found in
the 24 hr urine collection and the random urine protein-
to-creatinine ratio (Figure 3c) was significantly differentFigure 3 The relationships between the log transformed value of the
to-creatinine ratio in all subjects (a) and in the subjects without NS (b
protein-to creatinine ratio (c). Note that there was a strong linear depen
to-creatinine ratio. Solid line: linear regression, dotted lines: 95% confidencefrom that of the linear dependence between the log-
transformed value of the amount of 24 hr urinary
excreted Klotho and the random urine Klotho/Cr ratio
among the overall patients (z = 2.3, p = 0.0212) and the
patients without NS (z = 2.6, p = 0.0093). The random
urine Klotho/Cr did not trend towards lower values with
advancing stages of CKD (overall p = 0.058) (Figure 4a);
however, the random urine Klotho/Cr, as well as the
amount of 24 hr urinary excreted Klotho, correlated in-
versely with the stages of CKD (Spearman’s rho value =
−0.234, p < 0.01). The log-transformed random urine
Klotho/Cr was also associated with the eGFR
(Figure 4b); however, the log-transformed value of the
amount of 24 hr urinary excreted Klotho (ß = 0.407), but
not that of random urine Klotho/Cr, was identified as
a predictive variable for the eGFR (Total R2 = 0.166,
p < 0.01).
Discussion
The serum levels of soluble Klotho may be determined
by the level of FGF23, age, and renal function; however,
the current data are inconclusive, probably due to the
varied population of the subjects included in the studies
[6,9,10,16-19]. Moreover, there has been insufficient data
about the impacts of such parameters on the amount of
urinary excreted soluble Klotho among human subjects
with different disease status [6]. Although a decrease in
urinary Klotho levels in a relatively small number of
CKD patients was reported previously [20], our study
clearly demonstrated for the first time that not only the
serum Klotho concentration, but also the amount of
24 hr urinary excreted Klotho correlated with the eGFR
among the patients with various degrees of CKD. Besides
the finding that the serum Klotho concentration was
negatively correlated with age, which is consistent with
previous findings [9,10], we also confirmed that there
was a similar trend between the amount of urinary
excreted Klotho and the patient age. However, the24 hr urinary excreted Klotho level and that of the urine Klotho-
), and between the 24 hr urine protein and the random urine
dence between the 24 hr urine protein and the random urine protein-
intervals.
Figure 4 Box plots of the random urine Klotho/Cr by CKD stages and the relationship between the log-transformed random urine
Klotho/Cr and eGFR. (a) No trend towards the lower values of the random urine Klotho/Cr with advancing stages of CKD was statistically
confirmed. The lower border of the box and the upper border of the box represent the first quartile and third quartile, respectively. The whiskers
indicate 1.5 times the IR above and below the 25th and 75th percentiles. Outliers (values >1.5 times the IR) are represented by closed circles. (b) A
significant association between the log-transformed random urine Klotho/Cr and the eGFR was observed.
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Klotho levels among the overall patients with CKD
should be interpreted carefully, since our results demon-
strated that the eGFR, but not age, was one of the piv-
otal predictive variables for the amount of urinary
excreted Klotho in various CKD patients, while only the
serum calcitriol was identified as a predictor of the
serum soluble Klotho levels.
The renal upregulation of the Klotho gene expression
by exogenous calcitriol has been reported [21], while
Klotho itself has been demonstrated to play a role in the
regulation of calcitriol synthesis [22]. Therefore, it is not
surprising that the kinetics of soluble Klotho might also
be modulated by oral calcitriol or alfacalcidol, at least in
part, in some subsets of CKD patients in the current
study. However, most of the serum calcitriol levels of
such patients were below the normal range (data not
shown), which might be consistent with previous studies
[23,24]. Serum calcitriol was still included as a predictive
variable for the log-transformed serum Klotho concen-
tration when the nine patients who were treated with
oral vitamin D sterols were excluded (data not shown),
thus suggesting that the significance of exogenous active
vitamin D sterols on the levels of serum soluble Klotho
should be trivial among the patients in this study.
The renal synthesis of calcitriol, which is an active
form of vitamin D, is tightly regulated by serum levels of
PTH, calcium, and phosphorus [25]. FGF23, secreted
from the bone, also suppresses the production of calci-
triol at the level of renal proximal tubules [25,26]. Lack
of data on the levels of serum 25-hydroxyvitamin D,
which is the relevant indicator of exogenous supplies of
vitamin D [25], precludes us from evaluating the
biological significance of overall vitamin D metabolism
on the kinetics of soluble Klotho among patients withCKD included in the current study. Nevertheless, the in-
clusion of serum calcitriol as a predictive variable for the
log-transformed serum Klotho concentration (but not
for the log-transformed value of the amount of 24 hr
urinary excreted Klotho) despite the finding that the
serum levels of calcitriol negatively correlated with levels
of iPTH as well as those of FGF23 led us to propose the
specific role of calcitriol as a potential determinant for
serum soluble Klotho levels. This concept is strongly
supported by the recent demonstration of the Klotho ex-
pression in human vascular tissues, including vascular
smooth muscle cells, which is reduced during the course
of CKD and can be restored by exogenous calcitriol [27].
Although the biological significance of calcitriol on the
serum soluble Klotho levels and the amount of 24 hr ex-
cretion of urinary soluble Klotho should be evaluated
separately, the significant association between eGFR and
serum calcitriol levels demonstrated in this study implies
that the magnitude of functioning or viable nephrons
may ultimately determine the kinetics of both urinary
and serum soluble Klotho. On the other hand, neither
the amount of 24 hr urinary excreted Klotho nor the
serum soluble Klotho levels correlated with several para-
meters, including not only FGF23 and calcium found in
the serum but also with the amount of urinary excreted
sodium, calcium, potassium, and phosphorus (data not
shown), suggesting that the intrinsic role of the soluble
Klotho on the disruption of mineral metabolism asso-
ciated with various degrees of CKD might be marginal
[14,28].
In our previous study with the peritoneal dialysis (PD)
patients, we failed to confirm any significant associations
between the amount of urinary excreted Klotho and that
of albumin, which is the principal component of urinary
protein in cases of glomerular proteinuria [29,30].
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Klotho detected in PD subjects is not of glomerular ori-
gin, but rather originate exclusively from the renal
tubules [6]. This should be the case for the patients
without NS in this study as well. Indeed, the current
study demonstrated that the urinary Klotho level was
significantly associated with both the urinary total pro-
tein and the albumin level among the overall CKD
patients, while no such relationships were observed
when the patients with NS were excluded (data not
shown). We believe that such changes might be linked
to the disturbed glomerular permeability that arises from
various glomerulopathies associated with NS [29,31].
Therefore, the glomerular permeation of large mole-
cules, including soluble Klotho, should regulate the
amount of urinary excreted Klotho and the serum level
of Klotho by modulating the internal distribution of sol-
uble Klotho. Our recent analyses demonstrated approxi-
mately 30-50% decreases in the serum soluble Klotho
levels following retroperitoneoscopic nephrectomy in liv-
ing donors [32]. Preliminarily, however, we confirmed
the fact that soluble Klotho is detectable even in aneph-
ric chronic hemodialysis patients (data not shown).
Moreover, the recent demonstrations of the Klotho ex-
pression in vascular tissue encouraged us to regard the
vascular territory as another source of serum soluble
Klotho that needs to be better characterized [27]. Appar-
ently, further studies are required to better determine
the information about the kinetics of soluble Klotho,
which still remains poorly understood [16,20].
Quantitating the urinary excreted protein relies on
24 hr urine collection [33], while such procedures are
cumbersome and time consuming, which may lead to a
delay in evaluations and inaccurate results as a result of
poor compliance [34]. In this regard, the measurement
of the protein-to-creatinine ratio in single random urine
specimen has been focused on as an alternative ap-
proach that can be used to avoid the need for a 24 hr
urine collection [35,36]. This may not be the case with
quantitating urinary excreted Klotho since our study
revealed that the correlation coefficients of the linear de-
pendence between the log-transformed values of the
amount of 24-hr urinary excreted Klotho and the ran-
dom urine Klotho/Cr ratios among the overall patients
and the patients without NS were not comparable with
those of the linear dependence between the protein-to-
creatinine ratios in single random urine specimens and
the amounts of excreted protein found in 24-hr urine
collections, implying that the Klotho/Cr ratios in ran-
dom urine specimens do not serve as reliable surrogates
for the amount of 24-hr urinary excreted Klotho, regard-
less of the presence or absence of NS. Otherwise, varia-
tions in urinary Klotho excretion throughout the day,
similar to the variation observed in the urinary proteinlevels in a given human subject [37], may be present.
Moreover, the fact that the random urine Klotho/Cr
ratios trended towards lower values with advancing
stages of CKD and were significantly associated with
eGFR encouraged us to pursue extensive evaluations
regarding the clinical impact of measuring the random
urine Klotho/Cr ratios. In this regard, whether the opti-
mal timing of the collection of a single voided urine spe-
cimen to be used as an acceptable alternative to 24 hr
urine collection should be examined in larger subjects
with various stages of CKD, and is therefore currently
being investigated by our group.
Although the current study provided new information
regarding the urinary and serum soluble Klotho among
the various degrees of CKD patients, our results should
be interpreted within the context of their limitations.
There are several approximations of renal function, such
as the clearance of creatinine, inulin, radio-active mar-
kers or radio-contrast agents; however, these methods
are all impractical for everyday use and are not widely
available. In particular, the creatinine clearance exceeds
the GFR as a result of the tubular secretion of creatinine
in patients with severely progressed chronic renal failure
[6,29]. Therefore, the use of eGFR as an surrogate index
in the current study should be mandatory [6,29,38]. Fur-
thermore, multiple linear regression analyses may not
necessarily be the most appropriate procedure since the
correlation coefficients cannot replace visual examin-
ation of the data with precision. Nevertheless, such pro-
cedures combined with log-transformed variables may
not be exceptional [10,16,18,19]. On the other hand, the
data regarding the soluble Klotho in the current study
may be modified by the anti-hypertensive agents such as
renin-angitensin-system (RAS) inhibitors, which has
been demonstrated to be associated with the up-
regulation of renal Klotho expression [39]. In our sub-
jects, the prevalence of the patients treated with RAS
inhibitors trended towards greater values with advancing
stages of CKD (data not shown), thereby the distribution
of CKD stages were not comparable between the sub-
jects with RAS treatment and those without RAS treat-
ment, and this fact preclude us to precisely evaluate the
impact of such agents on the amount of urinary excreted
Klotho and the serum levels of soluble Klotho. Despite
these limitations, we believe our data have value, espe-
cially regarding the impact of residual renal function on
the amount of urinary excreted soluble Klotho and
serum soluble Klotho concentration among the CKD
subjects.
Conclusion
The magnitude of functioning nephrons should be
linked to the amount of urinary Klotho rather than the
serum Klotho levels among patients with CKD. The use
Akimoto et al. BMC Nephrology 2012, 13:155 Page 8 of 9
http://www.biomedcentral.com/1471-2369/13/155of the random urine Klotho/Cr ratio as a surrogate for
the amount of 24-hr urinary excreted Klotho needs to
be evaluated more carefully.
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